China Elderly Valve Disease Study III (China-DVD3 Study)

NCT07816146 · tracked via the Priya Life Science China tracker

Sponsor

Yongjian Wu, MD, PhD

Phase

Observational

Started

2026-09-07

Last updated

2026-09-11

Condition(s) studied

Heart Valve DiseasesModerate to Severe Valve Disease in the Elderly

Study summary

This study aims to conduct a second round of multicenter, prospective registry research targeting elderly patients with valvular heart disease, to understand the current status of interventions for patients with valvular heart disease. To systematically evaluate the distribution of types, clinical characteristics, interventions, and complications of elderly valvular heart disease, and to compare and analyze these with the China-DVD data from 2016, thereby revealing its evolutionary trends. By comprehensively considering various clinical characteristics such as different types of valvular lesions, treatment modalities, patient cardiac function, comorbidities, and blood test indicators, as well as multidimensional factors including psychological and lifestyle aspects, to deeply identify the key determinants influencing the treatment of elderly valvular heart disease patients in China, and thus optimize and improve their individualized comprehensive management pathways.

Eligibility

Sex

ALL

Min age

60 Years

Max age

—

Healthy volunteers

Inclusion Criteria: Hospitalized patients over 60 years old meet one of the following conditions. 1、 moderate or above valvular heart disease as defined by echocardiography: One of the following criteria * (1)Mitral stenosis : Valve area ≤1.5 cm², or mean pressure gradient ≥10 mmHg. * (2)Mitral regurgitation : Moderate and above regurgitation, or regurgitant jet width ≥ 3 mm, or regurgitant volume per beat ≥ 30 ml, or regurgitant jet area/left atrial area \> 20%; or effective regurgitant orifice area (EROA) ≥ 20 mm² * (3)Aortic stenosis : Moderate and above, mean pressure gradient ≥ 20 mmHg, or peak jet velocity ≥ 3 m/s, or valve area ≤ 1.5 cm² * (4)Aortic regurgitation : Moderate and above regurgitation, or regurgitant jet width ≥ 3 mm, or regurgitant volume per beat ≥ 30 ml, or regurgitant fraction ≥ 30%, or jet width occupying ≥ 25% of the left ventricular outflow tract, or effective regurgitant orifice area (EROA) ≥ 10 mm² * (5)Tricuspid stenosis : Moderate and above * (6)Tricuspid regurgitation : Moderate and above regurgitation, or jet area ≥ 5 cm² * (7)Pulmonary stenosis : Moderate and above * (8）Pulmonary regurgitation : Moderate and above regurgitation 2 、Previous history of cardiac valve surgery or interventional therapy (dilation, valvuloplasty, valve replacement) 3、Diagnosed with infective endocarditis Exclusion Criteria: Patients unwilling to accept registration and follow-up; * Patients with mental illness who cannot cooperate with information collection and follow-up Patients have been enrolled in this study.

Primary outcome measure(s)

First valve intervention during this hospitalization — From enrollment to the end of treatment at 12 weeks
Underwent their first internal medicine intervention or surgical procedure during hospitalization for valvular heart disease in this study

Trial sites (1)

Facility	City	Region	Status
Fuwai Hospital, National Center for Cardiovascular Diseases，Chinese Academy of Medical Sciences	Beijing	Beijing Municipality

Other trials for the same condition

Research on Optimal Diagnosis and Treatment of Cardiorenal Syndrome Recruiting

AI Assisted Screening for VHD Using Routine Chest CT Scans Recruiting

Prognosis Prediction System of Patients With Cardiovascular and Cerebrovascular Diseases Based on Multi-omics Recruiting

Transpacific TAVR Registry Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07816146 on ClinicalTrials.gov ↗ ← All trials in China